US2017218334A1PendingUtilityA1
Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
Est. expiryMar 13, 2029(~2.6 yrs left)· nominal 20-yr term from priority
C12N 5/0693G01N 33/5014C12N 5/0618C12N 5/00C12N 15/63C12N 5/0602G01N 33/5091G01N 33/586G01N 33/5058G01N 33/567C07K 16/1282Y02A50/30
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . An established single cell derived clonal cell line comprising cells susceptible to intoxication by botulinum toxin type A (BoNT/A),
wherein the cells exhibit at least a 1.5-fold increase in mRNA expression levels after differentiation in the genes ADAMTS9, ATAD2, CDC45L, CNTN1, Cyclin A, Cyclin E, E2F1, E2F2, E2F7, FGFR2, MYBL1, MYBL2, NDC80, NDN, ORC1L, PLS3, RAD54L, RBL1, RRM2, S1PR3, SPC24, SPC25, TFDP1, TFPI2, TK1, TTK, TYMS, TYK and ZWINT relative to the mRNA expression levels of each of these genes in cells from the parental SiMa cell line DSMZ ACC 164; and, wherein the cells exhibit at least a 1.5-fold decrease in mRNA expression levels after differentiation in the genes CDKN2A and CNTN2 as compared to the mRNA expression levels of each of these genes in cells from the parental SiMa cell line DSMZ ACC 164; and, wherein the clonal cell line comprises cells susceptible to BoNT/A intoxication by about 100 pM or less of a BoNT/A.
2 . The established clonal cell line of claim 1 , wherein the cells exhibit at least a 2.0-fold difference in gene expression levels of at least one gene as compared to the expression levels of the gene in cells from the parental SiMa cell line DSMZ ACC 164.
3 . The established clonal cell line of claim 1 , wherein the cells exhibit at least a 3.0-fold difference in gene expression levels of at least one gene as compared to the expression levels of the gene in cells from the parental SiMa cell line DSMZ ACC 164.
4 . The established clonal cell line of claim 1 , wherein the cells exhibit at least a 4.0-fold difference in gene expression levels of at least one gene as compared to the expression levels of the gene in cells from the parental SiMa cell line DSMZ ACC 164.
5 . The established clonal cell line of claim 1 , wherein the cell from an established clonal cell line exhibits about 100 pM or less of a BoNT/A for at least 5 or more cell passages.Join the waitlist — get patent alerts
Track US2017218334A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.